

FY2027.3 First Quarter

Financial Results Supplementary Materials

August 13, 2026

Japan System Techniques Co., Ltd. (Tokyo Stock Exchange Prime Market: 4323)

1. Summary

FY2027.3 First Quarter Financial Summary

Sales increased, while operating profit declined due to relocation costs, Brand business growth investments, and impacts from two specific projects. Net profit declined due to an impairment loss. Full-year forecasts remain unchanged.

Net sales

¥7,437 mn

YoY +5.6%

Operating profit

¥390 mn

YoY -21.0%

Ordinary profit

¥402 mn

YoY -21.0%

Profit attributable to
owners of parent

¥113 mn

YoY -64.8%



Continued sales growth

Net sales reached a record high for the sixth consecutive first quarter. Sales increased in all segments, led by DX & SI and Medical Big Data.



Profit decline factors identified

The main factors were one-time expenses related to the Tokyo Head Office relocation, planned growth investments in the Brand business, and adverse profitability impacts from two specific projects. The impacts from the specific projects are limited to those two projects.




Full-year forecasts unchanged

Given the second-half-weighted earnings structure, first-quarter progress was in line with plan. Full-year forecasts remain unchanged.

Source: FY2027.3 first quarter financial results.

Factors Behind Change in Operating Profit

Operating profit excluding one-time relocation expenses and adverse profitability impacts from two specific projects exceeded the prior-year level.



Reference: Operating profit excluding Tokyo Head Office relocation expenses and specific project impacts

¥527 mn YoY +6.9%

Calculated for reference only. This is not a financial measure under accounting standards.

Factor behind decline in quarterly profit (extraordinary loss)

¥155 mn Impairment loss on non-current assets

Related to the decision to sell an employee dormitory and not a recurring expense.

Source: FY2027.3 first quarter financial results and Company data. The vertical axis starts at 300 to show the scale of changes clearly.


Note: "Other factors" include growth investments in the Brand business. Adjusted operating profit excludes only Tokyo Head Office relocation expenses and adverse profitability impacts from two specific projects and is presented for reference purposes.

3. Progress Against Full-Year Forecasts


Progress Against Full-Year Forecasts and Earnings Seasonality

The first-quarter ordinary profit progress rate of 9.6% was broadly in line with the four-year average of 9.7%, reflecting a second-half-weighted earnings structure.

First-Quarter Ordinary Profit Progress Rate



Quarterly Breakdown of Operating Profit (Actual)



Full-year forecasts (¥ mn): Unchanged from initial forecasts

Net sales 34,300 / Operating profit 4,150 / Ordinary profit 4,200 / Net income 2,950

Source: Financial results for each fiscal year.

Note: Progress rate is first-quarter ordinary profit as a percentage of full-year actual results for each fiscal year. For FY2027.3, the initial full-year forecast is used.

©2026 Japan System Techniques Co., Ltd.

Segment Results

Sales increased in all segments. Package and Medical are in a ramp-up phase for growth investments and posted profit declines. Recovery is expected for the full year.

(¥ mn)

Segment	Net sales FY2027.3 Q1	Net sales FY2026.3 Q1	Inc./Dec.	Operating profit FY2027.3. Q1	Operating profit FY2026.3. Q1	Inc./Dec.
DX & SI	4,850	4,588	+262	820	821	-1
Package	1,444	1,397	+46	280	373	-92
Medical Big Data	650	566	+84	31	52	-20
Global	491	487	+3	-48	-89	+40
Corporate Expenses	-	-	-	-693	-664	-28
Total	7,437	7,039	+397	390	493	-103

Main Factors of Change (Operating Profit Basis)

DX & SI	Profitability exceeded prior Q1, excluding two project impacts.	Package	GAKUEN: Upfront growth investments and consulting capability build-up reduced profitability.
Medical Big Data	Growth investments and organizational strengthening for MDP expansion reduced profitability.	Global	Two Thai subsidiaries increased sales; expenses declined after prior-year impairment.
Corporate Expenses	Increased YoY due to one-time expenses for the Tokyo Head Office relocation, etc.		

Source: FY2027.3 1Q financial results and Company data.

Note: Changes include rounding differences. MDP (Medical Data Provision) is a package using medical data to support DX and research.

Capital Policy and Shareholder Returns

As part of disciplined capital allocation under the medium-term management plan, JAST is flexibly executing its first share repurchase.

Overview of Share Repurchase

Resolution date	June 26, 2026
Total shares to be acquired	Up to 2,000,000 shares (8.06% of total shares outstanding)
Total acquisition amount	Up to ¥2.5 bn
Acquisition period	July 1, 2026 to June 25, 2027
Acquisition method	Market purchases through a discretionary trading contract
Policy after acquisition	All acquired shares are expected to be cancelled, except those allocated to RS for employees, etc.

Shareholder Return Policy (Medium-Term Management Plan)

Payout ratio
50%

Total payout ratio
50% or more

ROE
20% or more

FY2027.3 annual dividend forecast: **¥50** (+¥5 YoY)

JAST aims to achieve capital efficiency exceeding the cost of capital while balancing reinvestment for growth and shareholder returns.

Reference: Since the share repurchase announcement, the share price has traded above the pre-announcement level.

Source: “Notice Concerning Decision on Matters Relating to Acquisition of Treasury Shares” (June 26, 2026) and Medium-Term Management Plan FY2027.3-FY2029.3 (announced May 14, 2026).

Note: Share prices are affected by market conditions and various other factors. This material does not indicate a causal relationship with any specific measure.

Management View and Initiatives on Generative AI

JAST is built on proprietary assets in regulated domains and views generative AI as an amplifier, not a substitute.

Market View of the Software Industry

Amid concerns about substitution by generative AI, the entire sector is being evaluated uniformly, regardless of differences in business models.

≠

JAST's Business Structure

JAST specializes in regulated domains such as education, healthcare, and financial services, with businesses embedded in customers' mission-critical operations. Substitution risk is structurally different.

Four Drivers That Define Resilience to Substitution



Proprietary Data Assets

Reusable data accumulated over many years in regulated domains



Institutional and Regulatory Expertise

Compliance with education, healthcare, and financial systems, plus high accuracy



Depth of Workflow Integration

Embedded in customers' mission-critical operations with high switching costs



Trust and Governance

Trust based on accountability and track record in handling sensitive data

Initiatives to Improve Productivity Using Generative AI

Based on priority strategies in the Medium-Term Management Plan, JAST is enhancing productivity through asset reuse and AI utilization.

1 Launch specialized team

Launched

Consolidate specialized talent



2 Pilot application to selected projects

In progress

Verification in large-scale SI development projects



3 Roll out to all business divisions

FY2028.3

Apply sequentially to projects and product development

Medium-Term Management Plan ROE
16.6% → 20.0% or more
FY2026.3 actual → final target

Source: Medium-Term Management Plan (announced May 14, 2026) and Company analysis. ROE figures are FY2026.3 actual and final target under the Medium-Term Management Plan.

Note: Productivity improvement effects are being measured through pilot projects. Measurement results are scheduled to be disclosed in future financial briefings.

Japan System Techniques Co., Ltd.

<https://www.jast.jp/en/>

Forward-looking statements such as forecasts in this material are based on information currently available to the Company and certain assumptions deemed reasonable by the Company. Actual results may differ significantly due to various factors.